Cardiovascular Diseases and Adipokines: The Role of Visfatin in Coronary Atherosclerosis

REVIEW
Zh. Marinova-Zlatinova, M. Negreva, Tr. Chervenkov

 
For citation: Marinova-Zlatinova Zh, Negreva M, Chervenkov Tr. Cardiovascular Diseases and Adipokines: The Role of Visfatin in Coronary Atherosclerosis. International Journal of Biomedicine. 2024;14(1):9-14. doi:10.21103/Article14(1)_RA1
 
Originally published March 1, 2024

Abstract: 

Coronary artery disease (CAD) is a leading cause of cardiovascular disease-related mortality globally. Traditional risk indicators for CAD, such as age, gender, hypertension, and cholesterol levels, may not reliably predict the existence and severity of the disease in all individuals. Furthermore, these risk variables may not provide information regarding the long-term prognosis and survival of the patients with stable CAD. The limitations of present screening approaches suggest the need to develop novel prognostic biomarkers for the detection of coronary atherosclerosis (CA).
This review focuses on the significance of adipokines in the pathophysiology of CA. The article discusses the role of various cytokines, focusing on visfatin in developing and progressing coronary atheroma and its potential to improve risk stratification, increase diagnostic accuracy, and guide therapy decisions. Clinical evidence supporting visfatin’s role as a diagnostic marker for CAD is already available, with elevated levels observed in patients with significant CA. However, the paper acknowledges certain limitations, such as the need for more extensive longitudinal studies to validate its potential use in clinical practice to improve early diagnosis and prognosis, ultimately enhancing strategies for preventing cardiovascular disease.

Keywords: 
visfatin • coronary artery disease • adipokines • biomarkers • screening
References: 
  1. Duggan JP, Peters AS, Trachiotis GD, Antevil JL. Epidemiology of Coronary Artery Disease. Surg Clin North Am. 2022 Jun;102(3):499-516. doi: 10.1016/j.suc.2022.01.007.
  2. Bauersachs R, Zeymer U, Brière JB, Marre C, Bowrin K, Huelsebeck M. Burden of Coronary Artery Disease and Peripheral Artery Disease: A Literature Review. Cardiovasc Ther. 2019 Nov 26;2019:8295054. doi: 10.1155/2019/8295054.
  3. The Global Burden of Disease Study 2017 (GBD 2017). Institute for Health Metrics and Evaluation (IHME), University of Washington; 2017.
  4. Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al.; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. Circulation. 2021 Feb 23;143(8):e254-e743. doi: 10.1161/CIR.0000000000000950
  5. Writing Group Members; Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al.; American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Executive Summary: Heart Disease and Stroke Statistics--2016 Update: A Report From the American Heart Association. Circulation. 2016 Jan 26;133(4):447-54. doi: 10.1161/CIR.0000000000000366.
  6. Medina-Leyte DJ, Zepeda-García O, Domínguez-Pérez M, González-Garrido A, Villarreal-Molina T, Jacobo-Albavera L. Endothelial Dysfunction, Inflammation and Coronary Artery Disease: Potential Biomarkers and Promising Therapeutical Approaches. Int J Mol Sci. 2021 Apr 8;22(8):3850. doi: 10.3390/ijms22083850.
  7. Ahmad A, Imran M, Ahsan H. Biomarkers as Biomedical Bioindicators: Approaches and Techniques for the Detection, Analysis, and Validation of Novel Biomarkers of Diseases. Pharmaceutics. 2023 May 31;15(6):1630. doi: 10.3390/pharmaceutics15061630.
  8. Chapman A, Adamson P, Shah A, Anand A, Strachan F, Lee KK, et al. High-sensitivity cardiac troponin and the fourth universal definition of myocardial infarction. Heart 2019;105:A118. doi: 10.1136/heartjnl-2019-bcs.141
  9. Netto J, Teren A, Burkhardt R, Willenberg A, Beutner F, Henger S, Schuler G, Thiele H, Isermann B, Thiery J, Scholz M, Kaiser T. Biomarkers for Non-Invasive Stratification of Coronary Artery Disease and Prognostic Impact on Long-Term Survival in Patients with Stable Coronary Heart Disease. Nutrients. 2022 Aug 20;14(16):3433. doi: 10.3390/nu14163433.
  10. Liu C, Chu D, Kalantar-Zadeh K, George J, Young HA, Liu G. Cytokines: From Clinical Significance to Quantification. Adv Sci (Weinh). 2021 Aug;8(15):e2004433. doi: 10.1002/advs.202004433. Epub 2021 Jun 10.
  11. Raucci R, Rusolo F, Sharma A, Colonna G, Castello G, Costantini S. Functional and structural features of adipokine family. Cytokine. 2013 Jan;61(1):1-14. doi: 10.1016/j.cyto.2012.08.036.
  12. lhan N, Susam S, Canpolat O, Belhan O. The emerging role of leptin, Adiponectin and Visfatin in Ischemic/Hemorrhagic stroke. Br J Neurosurg. 2019 Oct;33(5):504-507. doi: 10.1080/02688697.2019.1578862.
  13. Abdalla MMI. Role of visfatin in obesity-induced insulin resistance. World J Clin Cases. 2022 Oct 26;10(30):10840-10851. doi: 10.12998/wjcc.v10.i30.10840.
  14. Ashraf H, Soltani D, Sobh-Rakhshankhah A, Jafari S, Boroumand MA, Goudarzi V, Vasheghani Farahani A, Masoudkabir F. Visfatin as marker of isolated coronary artery ectasia and its severity. Cytokine. 2019 Jan;113:216-220. doi: 10.1016/j.cyto.2018.07.007.
  15. Duman H, Özyıldız AG, Bahçeci İ, Duman H, Uslu A, Ergül E. Serum visfatin level is associated with complexity of coronary artery disease in patients with stable angina pectoris. Ther Adv Cardiovasc Dis. 2019 Jan-Dec;13:1753944719880448. doi: 10.1177/1753944719880448.
  16. Dakroub A, A Nasser S, Younis N, Bhagani H, Al-Dhaheri Y, Pintus G, Eid AA, El-Yazbi AF, Eid AH. Visfatin: A Possible Role in Cardiovasculo-Metabolic Disorders. Cells. 2020 Nov 9;9(11):2444. doi: 10.3390/cells9112444.
  17. Pisani DF, Dumortier O, Beranger GE, Casamento V, Ghandour RA, Giroud M, Gautier N, Balaguer T, Chambard JC, Virtanen KA, Nuutila P, Niemi T, Taittonen M, Van Obberghen E, Hinault C, Amri EZ. Visfatin expression analysis in association with recruitment and activation of human and rodent brown and brite adipocytes. Adipocyte. 2015 Dec 9;5(2):186-95. doi: 10.1080/21623945.2015.1122854.
  18. Dimitriadis GK, Adya R, Tan BK, Jones TA, Menon VS, Ramanjaneya M, Kaltsas G, Miras AD, Randeva HS. Effects of visfatin on brown adipose tissue energy regulation using T37i cells. Cytokine. 2019 Jan;113:248-255. doi: 10.1016/j.cyto.2018.07.013.
  19. Chen HJ, Meng T, Gao PJ, Ruan CC. The Role of Brown Adipose Tissue Dysfunction in the Development of Cardiovascular Disease. Front Endocrinol (Lausanne). 2021 May 25;12:652246. doi: 10.3389/fendo.2021.652246.
  20. Funahashi T, Shimomura I, Matsuzawa Y. Adipocytokines. Encyclopedia of Endocrine Diseases. 2004;41–4. doi: 10.1016/b0-12-475570-4/01460-8.
  21. Deng Y, Scherer PE. Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann N Y Acad Sci. 2010 Nov;1212:E1-E19. doi: 10.1111/j.1749-6632.2010.05875.x. Erratum in: Ann N Y Acad Sci. 2011 May;1226(1):50.
  22. Mancuso P. The role of adipokines in chronic inflammation. Immunotargets Ther. 2016 May 23;5:47-56. doi: 10.2147/ITT.S73223.
  23. Roy P, Orecchioni M, Ley K. How the immune system shapes atherosclerosis: roles of innate and adaptive immunity. Nat Rev Immunol. 2022 Apr;22(4):251-265. doi: 10.1038/s41577-021-00584-1.
  24. Bugger H, Zirlik A. Anti-inflammatory Strategies in Atherosclerosis. Hamostaseologie. 2021 Dec;41(6):433-442. doi: 10.1055/a-1661-0020.
  25. Murphy SP, Kakkar R, McCarthy CP, Januzzi JL Jr. Inflammation in Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 Mar 24;75(11):1324-1340. doi: 10.1016/j.jacc.2020.01.014.
  26. Chaikijurajai T, Tang WHW. Reappraisal of Inflammatory Biomarkers in Heart Failure. Curr Heart Fail Rep. 2020 Feb;17(1):9-19. doi: 10.1007/s11897-019-00450-1.
  27. Held C, White HD, Stewart RAH, Budaj A, Cannon CP, Hochman JS, et al.; STABILITY Investigators. Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. J Am Heart Assoc. 2017 Oct 24;6(10):e005077. doi: 10.1161/JAHA.116.005077.
  28. Voudris KV, Chanin J, Feldman DN, Charitakis K. Novel Inflammatory Biomarkers in Coronary Artery Disease: Potential Therapeutic Approaches. Curr Med Chem. 2015;22(22):2680-9. doi: 10.2174/0929867322666150420124427.
  29. Li H, Sun K, Zhao R, Hu J, Hao Z, Wang F, Lu Y, Liu F, Zhang Y. Inflammatory biomarkers of coronary heart disease. Front Biosci (Landmark Ed). 2017 Jan 1;22(3):504-515. doi: 10.2741/4498.
  30. Lubrano V, Balzan S. Consolidated and emerging inflammatory markers in coronary artery disease. World J Exp Med. 2015 Feb 20;5(1):21-32. doi: 10.5493/wjem.v5.i1.21.
  31. Sahu B, Bal NC. Adipokines from white adipose tissue in regulation of whole body energy homeostasis. Biochimie. 2023 Jan;204:92-107. doi: 10.1016/j.biochi.2022.09.003.
  32. Farkhondeh T, Llorens S, Pourbagher-Shahri AM, Ashrafizadeh M, Talebi M, Shakibaei M, Samarghandian S. An Overview of the Role of Adipokines in Cardiometabolic Diseases. Molecules. 2020 Nov 9;25(21):5218. doi: 10.3390/molecules25215218.
  33. Kumari B, Yadav UCS. Adipokine Visfatin's Role in Pathogenesis of Diabesity and Related Metabolic Derangements. Curr Mol Med. 2018;18(2):116-125. doi: 10.2174/1566524018666180705114131.
  34. Amiri-Dashatan N, Koushki M, Hosseini H, Khodabandehloo H, Fathi M, Doustimotlagh AH, Rezaei-Tavirani M. Association between circulating visfatin and pre-eclampsia: a systematic review and meta-analysis. J Matern Fetal Neonatal Med. 2022 Jul;35(13):2606-2618. doi: 10.1080/14767058.2020.1789581.
  35. Mohammadi M, Moradi A, Farhadi J, Akbari A, Pourmandi S, Mehrad-Majd H. Prognostic value of visfatin in various human malignancies: A systematic review and meta-analysis. Cytokine. 2020 Mar;127:154964. doi: 10.1016/j.cyto.2019.154964.
  36. Dahl TB, Yndestad A, Skjelland M, Øie E, Dahl A, Michelsen A, et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation. 2007 Feb 27;115(8):972-80. doi: 10.1161/CIRCULATIONAHA.106.665893.
  37. Mazaherioun M, Hosseinzadeh-Attar MJ, Janani L, Vasheghani Farahani A, Rezvan N, Karbaschian Z, Hossein-Nezhad A. Elevated serum visfatin levels in patients with acute myocardial infarction. Arch Iran Med. 2012 Nov;15(11):688-92.
  38. Gisterå A, Hansson GK. The immunology of atherosclerosis. Nat Rev Nephrol. 2017 Jun;13(6):368-380. doi: 10.1038/nrneph.2017.51.
  39. Yang S, Yuan HQ, Hao YM, Ren Z, Qu SL, Liu LS, Wei DH, Tang ZH, Zhang JF, Jiang ZS. Macrophage polarization in atherosclerosis. Clin Chim Acta. 2020 Feb;501:142-146. doi: 10.1016/j.cca.2019.10.034.
  40. Liu H, Wu X, Gang N, Wang S, Deng W, Zan L, Yu S. Macrophage functional phenotype can be consecutively and reversibly shifted to adapt to microenvironmental changes. Int J Clin Exp Med. 2015 Feb 15;8(2):3044-53.
  41. Dahl T, Ranheim T, Holm S, Berge R, Aukrust P, Halvorsen B. Nicotinamide phosphoribosyltransferase and lipid accumulation in macrophages. Eur J Clin Invest. 2011 Oct;41(10):1098-104. doi: 10.1111/j.1365-2362.2011.02515.x.
  42. Zhang C, Zhu R, Wang H, Tao Q, Lin X, Ge S, Zhai Z. Nicotinamide Phosphate Transferase (NAMPT) Increases in Plasma in Patients with Acute Coronary Syndromes, and Promotes Macrophages to M2 Polarization. Int Heart J. 2018 Sep 26;59(5):1116-1122. doi: 10.1536/ihj.17-363.
  43. Kadoglou NP, Gkontopoulos A, Kapelouzou A, Fotiadis G, Theofilogiannakos EK, Kottas G, Lampropoulos S. Serum levels of vaspin and visfatin in patients with coronary artery disease-Kozani study. Clin Chim Acta. 2011 Jan 14;412(1-2):48-52. doi: 10.1016/j.cca.2010.09.012.
  44. Lu LF, Wang CP, Yu TH, Hung WC, Chiu CA, Chung FM, Tsai IT, Yang CY, Cheng YA, Lee YJ, Yeh LR. Interpretation of elevated plasma visfatin concentrations in patients with ST-elevation myocardial infarction. Cytokine. 2012 Jan;57(1):74-80. doi: 10.1016/j.cyto.2011.10.015.
  45. Wu XA, Xie G, Li XQ, Wu HT, Wang X. The value of serum visfatin in predicting in-stent restenosis of drug-eluting stents. Clin Chim Acta. 2018 Apr;479:20-24. doi: 10.1016/j.cca.2018.01.004.

Download Article
Received November 14, 2023.
Accepted December 12, 2023.
©2024 International Medical Research and Development Corporation.